BIIB
BIOGEN INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$252.71
+1.52%Jun 26, 2026, 13:56 UTC
Biogen completed its $5.6 billion acquisition of Apellis and is now integrating the biotech by terminating most of Apellis' research programs and eliminating a small number of research roles.
Source:Jun 5, 2026, 00:00 UTC
AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.
← PreviousPage 2